Home > Insider Trading > Filing (0001209191-21-027611)

Filing Details

Accession Number:: 0001209191-21-027611
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-04-20 18:07:10
Reporting Period:: 2021-04-16

Accepted Time:: 2021-04-20 18:07:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1708493	Harpoon Therapeutics Inc.	HARP	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1687078	Mpm Oncology Impact Management Lp	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1691428	L.p. Fund Impact Oncology Ubs	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721035	Mpm Oncology Impact Management Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721036	L.p. Management (Cayman) Fund Impact Oncology	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-04-16	5,547	$19.82	7,061,697	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-04-16	300	$20.56	7,061,397	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-04-19	9,956	$19.29	7,051,441	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-04-19	100	$20.08	7,051,341	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-04-20	21,415	$18.70	7,029,926	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-04-20	834	$19.09	7,029,092	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.
The shares were sold as follows: 4,875 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 672 by MPM Asset Management LLC ("AM LLC").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.41 to $20.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 314,229 by AM LLC and 3,841,525 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 264 by UBS Oncology and 36 by AM LLC.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 314,193 by AM LLC and 3,841,261 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 8,751 by UBS Oncology and 1,205 by AM LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 312,988 by AM LLC and 3,832,510 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 312,976 by AM LLC and 3,832,422 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 18,823 by UBS Oncology and 2,592 by AM LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.03 to $19.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 310,384 by AM LLC and 3,813,599 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 733 by UBS Oncology and 101 by AM LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 to $19.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 310,283 by AM LLC and 3,812,866 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.